Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
TRL1068 is expected to eliminate the pathogen-protecting biofilm in Chronic Rhinosinusitis,
thus making these bacteria substantially more susceptible to established antibiotic treatment
regimens. This initial study is to assess overall safety and pharmacokinetics (PK) of
TRL1068. The goal of the development program is to demonstrate effectiveness of TRL1068 in
difficult to treat bacterial infections such as in CRS.